Fiche société
Gustave Roussy, Cancer Campus, Grand Paris
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| anti-CD19 CAR-T cellsThis is an open-label, single-dose, prospective, monocenter, Phase I interventional study (not first-in-human) to assess the safety, tolerability, and preliminary efficacy of autologous anti-CD19 CAR-T cells as an advanced therapy medicinal product in adult patients; with severe and refractory systemic autoimmune rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren's disease (SjD), systemic sclerosis (SSc) and idiopathic inflammatory myositis (IIM). | Lupus, Myopathies | Phase 1 | Immunomodulation + Thérapie cellulaire | France | À vérifier |
| anti-CD19 CAR-T cellsThis is an open-label, single-dose, prospective, monocenter, Phase I interventional study (not first-in-human) to assess the safety, tolerability, and preliminary efficacy of autologous anti-CD19 CAR-T cells as an advanced therapy medicinal product in adult patients; with severe and refractory systemic autoimmune rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren's disease (SjD), systemic sclerosis (SSc) and idiopathic inflammatory myositis (IIM). | Lupus | Phase 1 | Immunomodulation + Thérapie cellulaire | France | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| anti-CD19 CAR-T cells | Lupus | Phase 1 | NCT07544225 | CELL-ATTACK 1 — Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases | NOT_YET_RECRUITING |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| anti-CD19 CAR-T cells | Decade-long persistence of CD19 CAR T cells in B cell lymphomas. | Nature medicine | ||
| anti-CD19 CAR-T cells | Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series. | Cell reports. Medicine |